Burning Rock Biotech EPS - Earnings per Share 2021-2024 | BNR
Burning Rock Biotech eps - earnings per share from 2021 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Burning Rock Biotech Annual EPS | |
|---|---|
| 2024 | $-4.61 |
| 2023 | $-9.00 |
| 2022 | $-13.60 |
| 2021 | $-12.00 |
| 2020 | $-10.50 |
| 2019 | $0.00 |
| Burning Rock Biotech Quarterly EPS | |
|---|---|
| 2024-12-31 | $-4.26 |
| 2024-09-30 | $-0.05 |
| 2024-06-30 | $-0.14 |
| 2024-03-31 | $-0.16 |
| 2023-12-31 | $-2.30 |
| 2023-09-30 | $-2.30 |
| 2023-06-30 | $-1.80 |
| 2023-03-31 | $-2.60 |
| 2022-12-31 | $-2.90 |
| 2022-09-30 | $-3.10 |
| 2022-06-30 | $-3.70 |
| 2022-03-31 | $-3.90 |
| 2021-12-31 | $-4.00 |
| 2021-09-30 | $-2.50 |
| 2021-06-30 | $-3.00 |
| 2021-03-31 | $-2.50 |
| 2020-12-31 | $0.00 |
| 2020-09-30 | $-1.80 |
| 2020-06-30 | $-3.80 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Business Services | Technology Services | $0.029B | $0.071B |
| Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients as well as NGS-based cancer early detection. Burning Rock Biotech Limited is based in GUANGZHOU, China. | |||